<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk in patients with <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> is important because it determines screening, surveillance, and treatment considerations </plain></SENT>
<SENT sid="1" pm="."><plain>Previously, the risk of progression to esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> in patients with <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> was thought to be approximately 1% </plain></SENT>
<SENT sid="2" pm="."><plain>Recently, 2 very large population-based studies have significantly reduced this risk estimate of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Paradoxically, esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> continues to rise exponentially in the United States </plain></SENT>
<SENT sid="4" pm="."><plain>Screening and surveillance programs based on endoscopic, histopathological, and molecular criteria need to be improved to identify a high-risk population of progressors </plain></SENT>
</text></document>